Work Here?
Overview
MedPharm is a contract development and manufacturing organization specializing in topical, transdermal, and mucosal drug delivery. It provides end-to-end services from formulation development through clinical and commercial manufacturing, including analytical testing and regulatory support, and operates proprietary delivery platforms such as MedSpray, MedTherm, and AquaRMed. Its capabilities cover dermal, pulmonary, nasal, ophthalmic, and other mucosal routes, combining research services with a patent portfolio to support product lifecycle needs. In 2024 it merged with Tergus Pharma to expand into hormone-based and highly potent drugs, with the goal of helping pharmaceutical and biotech customers move from early formulation to scalable, reliable manufacturing for clinical and commercial use.
About MedPharm
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Grant
Total Funding
$390K
Headquarters
Guildford, United Kingdom
Founded
1999
Simplify's Take
What believers are saying
- February 2025 CEO Bill Humphries signals post-merger growth execution and commercial discipline.
- The Durham $4 million expansion created space for over 100 skilled hires in RTP.
- Palvella's positive March 2026 Phase 3 readout and Purna partnership strengthen sponsor validation.
What critics are saying
- MedPharm depends on niche topical spending; a sponsor slowdown hits utilization fast in 2025-2026.
- The 2024 merger left some Tergus leaders exiting, creating integration and execution risk.
- Topical CDMO giants and captive pharma plants can compress margins and steal repeat programs.
What makes MedPharm unique
- MedPharm remains the topical and transepithelial CDMO specialist after the 2024 Tergus merger.
- Durham and Guildford sites give MedPharm integrated development, clinical manufacturing, and commercial production.
- August 2026 Olink CSP status adds proprietary proteomics beyond formulation and in vitro testing.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$390k
Above
Industry Average
Funded Over
1 Rounds
Company News
MedPharm, a Guildford, UK-based topical and transdermal Contract Development and Manufacturing Organization (CDMO) and Ampersand Capital Partners portfolio company, announced a merger with Tergus Pharma, a Research Triangle Park, NC-based end-to-end contract service provider and a Great Point Partners portfolio company
MedPharm, a UK-based CDMO, has merged with Tergus Pharma, a US-based contract service provider. The combined entity will operate under the MedPharm name, offering end-to-end drug development and manufacturing services. Michael Kane, Tergus Pharma CEO, will become CEO of MedPharm, while Patrick Walsh remains Executive Chairman. Great Point Partners retains a significant minority stake, with Ampersand Capital Partners and Bourne Partners Strategic Capital holding majority ownership.
MedPharm is Hiring for 19 Jobs on Simplify!
Find jobs on Simplify and start your career today
About MedPharm
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
N/A
Company Stage
Grant
Total Funding
$390K
Headquarters
Guildford, United Kingdom
Founded
1999
MedPharm is Hiring for 19 Jobs on Simplify!
Find jobs on Simplify and start your career today